Thymosin Beta-1
Also known as Tbeta-1 · TB-1
Less-studied thymosin-family peptide discussed for immune modulation with sparse human evidence.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
Thymosin Beta-1 evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
medium
Regulatory
not approved
WADA
none
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Thymosin Beta-1 is a comparatively obscure thymosin-family peptide discussed in immune-support circles. It is much less studied than thymosin alpha-1 or thymosin beta-4, so most claims are extrapolations rather than conclusions from solid human evidence.
Decision path
Where Thymosin Beta-1 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Thymosin Beta-1 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Putative immune-modulating and cytoskeletal signaling roles inferred from thymosin-family biology.
subcutaneous, intramuscular
No well-established human dosing standard; gray-market use is mostly anecdotal.
Theoretical immune-support and inflammatory-modulation effects only.
Unknown; immune-signaling outcomes would be expected over days to weeks if present.
Use caution in autoimmune disease or where immune stimulation is undesirable.
Sparse formal safety data; injection reactions and unpredictable immune signaling remain the main practical concerns.
No clear interaction data; avoid confident multi-immune stack claims.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Thymosin Beta-1.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.